Trials / Completed
CompletedNCT05254847
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With Biliary Tract Cancer: A Single-arm, Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, single-center clinical study, to evaluate the efficacy and safety of Capecitabine combined with Lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine combined with lenvatinib and tislelizumab | Capecitabine combined with lenvatinib and tislelizumab |
Timeline
- Start date
- 2022-02-24
- Primary completion
- 2023-12-31
- Completion
- 2025-12-31
- First posted
- 2022-02-24
- Last updated
- 2026-01-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05254847. Inclusion in this directory is not an endorsement.